Exhibit 99.1 Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates Reaffirms guidance for the Phase 2a RIVER trial of Had uvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressing in the Phase 2b CORAL dose-ranging trial of Haduvio for the treatment of chronic cough in IPF patients Human Abuse Potential Study more than 50% enrolled Management to host a conference call and webcast today at 4:30 p.m. ET New Haven, Co ...